Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMYGet Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 83,900 shares, an increase of 20.2% from the April 15th total of 69,800 shares. Based on an average daily trading volume, of 1,006,700 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Stock Down 1.0 %

Astellas Pharma stock opened at $9.62 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91. Astellas Pharma has a one year low of $9.15 and a one year high of $16.91. The company has a 50-day simple moving average of $10.29 and a 200-day simple moving average of $11.21. The firm has a market capitalization of $17.41 billion, a P/E ratio of 137.43, a P/E/G ratio of 1.69 and a beta of 0.37.

Astellas Pharma (OTCMKTS:ALPMYGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $0.11 EPS for the quarter. The firm had revenue of $2.79 billion during the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. As a group, equities analysts expect that Astellas Pharma will post 0.44 earnings per share for the current year.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.

Featured Stories

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with's FREE daily email newsletter.